La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PharmaSGP Holding Salute del bilancio

Salute finanziaria criteri di controllo 5/6

PharmaSGP Holding ha un patrimonio netto totale di €44.7M e un debito totale di €73.2M, che porta il suo rapporto debito/patrimonio netto a 163.9%. Le sue attività totali e le sue passività totali sono rispettivamente €140.9M e €96.3M. L'EBIT di PharmaSGP Holding è €26.3M rendendo il suo rapporto di copertura degli interessi 7.4. Ha liquidità e investimenti a breve termine pari a €46.3M.

Informazioni chiave

163.9%

Rapporto debito/patrimonio netto

€73.21m

Debito

Indice di copertura degli interessi	7.4x
Contanti	€46.27m
Patrimonio netto	€44.67m
Totale passività	€96.26m
Totale attività	€140.93m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €73.9M ) di PSG superano le sue passività a breve termine ( €29.2M ).

Passività a lungo termine: Le attività a breve termine di PSG ( €73.9M ) superano le sue passività a lungo termine ( €67.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 60.3% ) di PSG è considerato alto.

Riduzione del debito: Cinque anni fa, PSG aveva un patrimonio netto negativo, ma ora è positivo e quindi è migliorato.

Copertura del debito: Il debito di PSG è ben coperto dal flusso di cassa operativo ( 37.8% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di PSG sono ben coperti dall'EBIT ( 7.4 x copertura).

PharmaSGP Holding Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Price target increased by 9.2% to €38.75

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Consensus EPS estimates increase by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

Analysts lower EPS estimates to €0.95

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

New 90-day low: €19.76

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Market pulls back on stock over the past week

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Analysts lower EPS estimates to €1.13

New 90-day low: €27.00

New 90-day low: €28.75

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane